Palynziq (pegvaliase-pqpz) is a phenylalaninemetabolizing enzyme indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria.
Abiraterone Acetate (Tablets)
Company: Sun Pharmaceutical Industries Inc. Date of Approval: May 22, 2018 Yonsa (abiraterone acetate) is an ultramicrosize formulation of the oral CYP17 inhibitor abiraterone acetate (approved as Zytiga) used in combination with methylprednisolone for the treatment of metastatic castration-resistant prostate cancer.
Avatrombopag (Tablets)
Company: Dova Pharmaceuticals, Inc. Date of Approval: May 21, 2018 Doptelet (avatrombopag) is a second generation, orally administered thrombopoietin receptor agonist (TPO-RA) indicated for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a medical procedure.
Sodium Zirconium Cyclosilicate (Oral Suspension)
Company: AstraZeneca Date of Approval: May 18, 2018 Lokelma (sodium zirconium cyclosilicate) is a potassium binder indicated for the treatment of hyperkalemia in adults.
Erenumab-Aooe (Injection)
Company: Amgen Inc. Date of Approval: May 17, 2018 Aimovig (erenumab-aooe) is a calcitonin generelated peptide (CGRP) receptor antagonist indicated for the preventive treatment of migraine.
lofexidine Hydrochloride (Tablets) Company: US WorldMeds Date of Approval: May 16, 2018
Lucemyra (lofexidine hydrochloride) is a selective 2-adrenergic receptor agonist indicated for reducing the severity of withdrawal symptoms in patients experiencing opioid withdrawal.
Epoetin Alfa-Epbx (Injection)
Company: Hospira, Inc. Date of Approval: May 15, 2018
Retacrit (epoetin alfa-epbx) is an erythropoiesisstimulating agent (ESA) biosimilar to Epogen/Procrit (epoetin alfa) indicated for treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery.
Polyethylene glycol 3350 with electrolytes (Oral Solution)
Company: Salix Pharmaceuticals, Inc. Date of Approval: May 4, 2018
Plenvu (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride) is a lower-volume, polyethylene glycol based osmotic laxative indicated for cleansing of the colon (bowel preparation) prior to colonoscopy.
Coagulation factor Xa (recombinant), inactivatedzhzo
Company: Portola Pharmaceuticals, Inc. Date of Approval: May 3, 2018
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) is a recombinant modified human Factor Xa (FXa) protein indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
Tolvaptan (Tablets)
Company: Otsuka Pharmaceutical Co., Ltd Date of Approval: April 23, 2018
Jynarque (tolvaptan) is a selective vasopressin V 2receptor antagonist indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).
Fosnetupitant and palonosetron
Company: Helsinn Healthcare SA Date of Approval: April 19, 2018
Akynzeo
for Injection (fosnetupitant and palonosetron) is a substance P/neurokinin-1 (NK-1) receptor antagonist and serotonin-3 (5-HT3) receptor antagonist combination indicated for use with dexamethasone for the prevention of chemotherapyinduced nausea and vomiting (CINV).
Burosumab-twza (Injection)
Company: Ultragenyx Pharmaceutical Inc. Date of Approval: April 17, 2018
Crysvita (burosumab-twza) is a fibroblast growth factor 23 (FGF23) blocking antibody for the treatment of x-linked hypophosphatemia (XLH).
Fostamatinib (Tablets)
Company: Rigel Pharmaceuticals, Inc. Date of Approval: April 17, 2018
Tavalisse (fostamatinib) is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of patients with chronic immune thrombocytopenia (ITP).
Ibalizumab-uiyk (Injection)
Date of Approval: March 6, 2018 Company: TaiMed Biologics USA Corp.
Trogarzo (ibalizumab-uiyk) is a CD4-directed postattachment HIV-1 inhibitor for the treatment of multidrug resistant human immunodeficiency virus-1 (HIV-1) infection in heavily treatment-experienced adults.
Tildrakizumab-asmn (Injection)
Date of Approval: March 20, 2018 Company: Sun Pharmaceutical Industries Ltd.
Ilumya (tildrakizumab-asmn) is a humanized, anti-IL-23p19 monoclonal antibody for the treatment of moderate-to-severe plaque psoriasis.
Efavirenz, lamivudine and tenofovir disoproxil fumarate (Tablets)
Date of Approval: March 22, 2018 Company: Mylan N.V.
Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) is a three-drug combination of a non-nucleoside reverse transcriptase inhibitor (efavirenz), and two nucleo(t)side reverse transcriptase inhibitors (lamivudine and tenofovir disoproxil fumarate) indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Certolizumab pegol (Injection) Cimzia (certolizumab) is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. New Indication Approved: May 25, 2018
Source: Drugs.com
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Denosumab (Injection)
Prolia is a RANK ligand (RANKL) inhibitor indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, for the treatment of bone loss in patients with prostate or breast cancer undergoing hormone ablation therapy, as a treatment to increase bone mass in men with osteoporosis at high risk for fracture, and for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture. New Indication Approved: May 18, 2018
Ixekizumab (Injection)
Taltz (ixekizumab) is a humanized interleukin-17A antagonist indicated for the treatment of plaque psoriasis and psoriatic arthritis. New Indication Approved: May 17, 2018 Tocilizumab (Injection) Actemra (tocilizumab) is a humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody for the treatment of rheumatoid arthritis; systemic juvenile idiopathic arthritis (SJIA); polyarticular juvenile idiopathic arthritis (PJIA); giant cell arteritis; and CAR T cell-induced severe or life-threatening cytokine release syndrome. New Dosage Regimen: May 11, 2018
Daratumumab (Injection)
Darzalex (daratumumab) is a human anti-CD38 monoclonal antibody indicated for the treatment of patients with multiple myeloma. New Indication Approved: May 7, 2018
Tisagenlecleucel (Suspension for Intravenous Infusion)
Kymriah (tisagenlecleucel) is a chimeric antigen receptor T cell (CAR-T) therapy for use in patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) and patients with relapsed or refractory (r/r) large B-cell lymphoma. New Indication Approved: May 1, 2018
Mirabegron (Extended Release Tablets)
Myrbetriq (mirabegron) is a -3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. New Indication Approved: April 27, 2018
Osimertinib (Tablets)
Tagrisso (osimertinib) is a tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) indicated for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer. New Indication Approved: April 18, 2018
Nivolumab (Injection)
Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody for the treatment of advanced melanoma, advanced non-small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, advanced squamous cell carcinoma of the head and neck, urothelial carcinoma, MSI-H or dMMR metastatic colorectal cancer and hepatocellular carcinoma. New Indication Approved: April 16, 2018
Everolimus (Tablets)
Afinitor (everolimus) is an oral once-daily inhibitor of mTOR indicated for the treatment of patients with advanced HR+, HER2-breast cancer; progressive neuroendocrine tumors of pancreatic origin (PNET); progressive neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin; advanced renal cell carcinoma; and subependymal giant cell astrocytoma (SEGA) and renal angiomyolipomas associated with tuberous sclerosis. New Indication Approved: April 10, 2018
Rucaparib (Tablets)
Rubraca (rucaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of patients with deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies; and for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. New Indication Approved: April 6, 2018
Bupivacaine liposome (Injectable Suspension)
Exparel (bupivacaine liposome injectable suspension) is a long-acting non-opioid local analgesic for postsurgical local analgesia, and for use as a nerve block (interscalene brachial plexus block) to provide pain relief following shoulder surgeries. New Indication Approved: April 6, 2018 
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Bowel Cancer: Low-calorie soft drinks could reduce recurrence Published: July 20, 2018 By Catharine Paddock PhD Consuming artificially sweetened soft drinks such as diet colas may be linked to a significantly lower risk of cancer return or death in patients with stage 3 colorectal cancers.
Are essential oils safe for babies?
Last reviewed Friday 20 July 2018 By Amanda Barrell Reviewed by Carissa Stephens, RN, CCRN, CPN There is some evidence for the benefits of essential oils, but very little research on how these oils may affect babies. It is crucial to note that the American Association of Naturopathic Physicians do not recommend using essential oils at all on babies younger than 3 months.
How long does nicotine stay in your system?
Last reviewed Thursday 19 July 2018 By Danielle Dresden Reviewed by Alan Carter, PharmD When people use tobacco products, some of the nicotine stays in their system after they quit smoking. Medical tests can detect nicotine in people's urine, blood, saliva, hair and nails. Nicotine is the addictive substance in tobacco, cigarettes and vapes or ecigarettes.
When someone smokes a cigarette, their body absorbs up to 90 percent of the nicotine. Traces of nicotine will linger long after individuals no longer feel the effects. After smoking a cigarette, nicotine and its by-products stay in a person's urine and saliva for 4 days and blood for up to 10 days.
Eating dinner earlier could reduce cancer risk
Published Thursday 19 July 2018 By Tim Newman According to a study that was conducted at the Barcelona Institute for Global Health in Spain, eating your final meal of the day too late can increase the risk of developing cancer. The relationship between food and cancer has been investigated to a great deal. For instance, regularly eating fresh vegetables has been shown to reduce cancer risk. Conversely, regularly eating red meat increases the risk of certain cancers. A recent study investigated potential links between meal timing and two common types of cancer: prostate cancer and breast cancer.
Source: medicalnewstoday.com
Non-dairy beverages like soy and almond milk may not be 'milk,' FDA suggests By Lindsey Ellefson, CNN Updated: July 19, 2018 (CNN)Got milk? If you're buying "milk" made with non-dairy products like almonds or oats, the US Food and Drug Administration isn't so sure you do. During a the Politico Pro Summit on Tuesday, FDA Commissioner Dr. Scott Gottlieb questioned whether the "standards of identity" applied to milk in the United States are being enforced correctly. The FDA describes milk as "the lacteal secretion, practically free from colostrum, obtained by the complete milking of one or more healthy cows." That definition doesn't leave room for vegan alternatives to call themselves "milk," though a number of products on the market do.
Non-dairy milks, including soy, almond, rice and coconut milk are juices from nuts, seeds, grains and legumes that may be fortified with vitamins and minerals to deliver the equivalent nutrient profile and sometimes taste and consistency of cow's milk.
Source: cnn.com/health
The risk of having a heart attack while pregnant, giving birth, or during the two months after delivery, continues to increase for American women, a new study finds.
